EZH2 and Miyoshi myopathy: Also, when combined with UNC1999, an inhibitor of EZH2 or JQ1, a BET bromodomain inhibitor, PTC-209 exhibited both synergistic and additive effects in MM (INA-6, JJN3, RPMI-8226, and LP-1) cancer cell lines (Alzrigat et al., 2017).